Page last updated: 2024-11-12
lactonamycin
Description
lactonamycin: isolated from Streptomyces rishiriensis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
lactonamycin : An organic heterohexacyclic compound isolated from the culture broth of Streptomyces rishiriensis. It is an antibiotic with antibacterial activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (4)
Synonym |
lactonamycin |
CHEBI:66553 |
(3as,5as,14ar)-9,13-dihydroxy-5a-{[(2s,5s,6s)-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-3a-methoxy-11-methyl-3,3a,11,12-tetrahydro-2h,5h-furo[2'',3'':4',5']furo[3',4':6,7]naphtho[2,3-e]isoindole-2,6,10,14(5ah)-tetrone |
Q27135163 |
Roles (3)
Role | Description |
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
antibacterial agent | A substance (or active part thereof) that kills or slows the growth of bacteria. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
Class | Description |
organic heterohexacyclic compound | |
gamma-lactone | A lactone having a five-membered lactone ring. |
trideoxyhexose derivative | A deoxyhexose derivative that is formally obtained from a trideoxyhexose. |
phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (20)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (20.00) | 18.2507 |
2000's | 11 (55.00) | 29.6817 |
2010's | 5 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.14
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 19.14 (24.57) | Research Supply Index | 3.04 (2.92) | Research Growth Index | 4.55 (4.65) | Search Engine Demand Index | 15.26 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |